ABSTRACT Streptomyces has an extensive natural product repertoire, including most of the naturally derived antibiotics. Understanding the control of natural product biosynthesis is central to antibiotic discovery and production optimization. Here, Hou et al. (J. Bacteriol. 200:00447-17, 2018, https://doi.org/10.1128/JB.00447-17) report the identification and characterization of a novel regulator-LmbU-that functions primarily as an activator of lincomycin production in Streptomyces lincolnensis. Importantly, members of this new regulator family are associated with natural product biosynthetic clusters throughout the streptomycetes and their actinomycete relatives.
thetic gene clusters. These strategies have included everything from heterologous expression of gene clusters within natural and engineered hosts to synthetic biology approaches that completely refactor the pathway (e.g., removing noncoding DNA and transcription factors and replacing them with synthetic regulatory components) (10, 11) . Within native strains, a range of genetic strategies have been employed to improve metabolite production, including the use of promoter knockins, overexpression of cluster-specific activators or global regulators, and deletion of cluster-specific repressors (11, 12) . While these strategies often yield some level of metabolite production, it is commonly coupled with suboptimal regulation and an unbalanced metabolic burden, which can lead to the accumulation of undesired intermediates or side products. Consequently, a comprehensive understanding of metabolic regulation is critically needed in order to fully exploit the metabolic potential of the streptomycetes.
There is considerable flexibility in the innate cluster regulatory schemes: some metabolic clusters lack any obvious regulatory genes, while others harbor multiple regulators. While regulators of many types have been found within biosynthetic clusters, a few classes are represented far more frequently than others (Table 1) . Known as either "pathway-specific" or "cluster-situated" regulators, these transcription factors primarily act to modulate the expression of genes within their cognate cluster. The SARPs-or Streptomyces antibiotic regulatory proteins-are among the most common and the best studied in the streptomycetes. These proteins are classified as members of the OmpR family of regulators, having an N-terminal winged helix-turn-helix DNA binding domain (24) . They are potent activators of their associated biosynthetic pathways, and overexpressing these genes has proven to be a powerful means of enhancing the production of their cognate metabolite (25) (26) (27) . Similarly, the members of the LAL family of regulators (for large ATPbinding regulators of the LuxR family) are also largely confined to the streptomycetes and, like the SARPs, function to activate the expression of their specific biosynthetic pathway (28) . Less well understood are the StrR-like regulators, which also have cluster-specific activator functions (21, 22) .
Negative cluster regulation is commonly mediated by TetR and GntR family members. Members of the TetR family in particular are frequently found in association with-and controlling-the expression of adjacent resistance/transporter determinants (29) . The activity of both TetR and GntR regulators is mediated by ligand binding (29, 30) . This typically results in a conformational change in the regulator, release of DNA binding, and a concomitant relief of repression.
Despite significant advances in our understanding of Streptomyces gene regulation, a reasonable proportion of natural product biosynthetic gene clusters do not appear to encode any obvious pathway-specific regulators. This suggests that our knowledge of gene expression in these bacteria-and, in particular, the control of these biosynthetic clusters-remains incomplete. This also raises several important questions. How are these natural product pathways regulated? How many novel regulators have yet to be identified, and how do they function?
One natural product biosynthetic gene cluster whose regulation is poorly understood is (32) . Lincomycin has been subjected to considerable derivatization, the most notable manifestation of which is clindamycin, a chlorinated variant with improved antibiotic activity. To date, genetic and biochemical studies have focused on elucidating the genes and enzymes responsible for synthesizing the precursors propylhygric acid (a nonproteogenic amino acid) and the sugar methylthiolincosamide and their subsequent conjugation to form the mature antibiotic (32) . In this issue, Hou et al. revisit the lincomycin biosynthetic pathway and shed light on its regulation (23) . Bioinformatic analysis of the lincomycin gene cluster in S. lincolnensis suggested that gene lmbU encodes a novel cluster-situated regulator. To test this hypothesis, the authors first inactivated lmbU and found that this mutation abolished lincomycin production. In contrast, overexpressing this gene resulted in a 5-fold increase in the lincomycin titer compared with the wild-type strain. To determine whether this effect stemmed from altered regulation, transcript levels for select genes throughout the cluster were assessed in the wild-type, lmbU mutant, and lmbU overexpression strains. Consistent with the lincomycin production experiments, transcript levels were significantly decreased for four of the biosynthetic genes tested (lmbA, lmbC, lmbJ, and lmbW) in the lmbU disruption strain, while the opposite effect was seen for several genes in the overexpression strain, where the expression of lmbA and lmbJ was increased. To validate these observations and to gain further insight into the in vivo function of lmbU, each predicted promoter region in the lincomycin gene cluster was fused to a neomycin resistance (Neo r ) gene cassette and subsequently introduced into both the wild-type S. lincolnensis strain and lmbU mutant strain. The results largely confirmed the previous experiments; however, it also became apparent that LmbU did not function solely as an activator. Higher kanamycin resistance (reporter activity) was observed for the lmbU and lmbK promoter fusions in the lmbU mutant background, suggesting that LmbU may serve (directly or indirectly) to repress the expression of these genes.
To address the mechanistic basis of LmbU activity, recombinant LmbU was overexpressed and purified. Electrophoretic mobility shift assays (EMSAs) were performed to test whether the observed effects were due to direct control by LmbU. LmbU was found to bind directly to the putative promoter sequences of lmbA and lmbW. Systematic deletion and mutagenesis of the sequence within the lmbV-lmbW intergenic region ultimately identified a palindromic DNA motif (5=-CGCCGGCG-3=) critical for LmbU binding. Indeed, S. lincolnensis strains containing the Neo r gene fused to an lmbA promoter variant lacking this sequence were sensitive to kanamycin, confirming the in vivo function of the motif for LmbU regulation. It appeared that the LmbU effect on the expression of lmbC, lmbJ, lmbK, and lmbU was indirect, as no binding to these promoter regions was observed using EMSAs. Intriguingly, this suggests that LmbU comprises only one piece of a complex network governing lincomycin biosynthesis.
With the discovery and characterization of LmbU activity, that study has established a new branch in the regulatory hierarchy governing natural product biosynthesis in the streptomycetes and their relatives. Future investigations into LmbU biochemistry and its protein structure will ultimately uncover the molecular mechanisms underpinning its function. Still unknown is how the activity of LmbU is integrated with that of other regulators and where it fits in the regulatory interplay coordinating Streptomyces differentiation and specialized metabolism. Nevertheless, a comprehensive understanding of LmbU function may expand the repertoire of tools available for use in the genetic engineering of these bacteria. Excitingly, lmbU homologs are associated with diverse natural product gene clusters in taxonomically disparate strains. Manipulating these genes may provide access to new natural product leads and ultimately help with replenishing the dwindling supply of effective antibiotics available to combat drug-resistant pathogens.
